A carregar...

Phase I study of mitozantrone, methotrexate and mitomycin with granulocyte colony-stimulating factor (filgrastim) in patients with advanced breast cancer.

The combination of mitozantrone, methotrexate and mitomycin (3M) gives a response rate of around 50% in patients with advanced breast cancer. The predominant toxicity is haematological. In this study, previously untreated patients were given 3M with increasing doses of mitozantrone (7-14 mg m-2) wit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: O'Brien, M. E., Nicolson, M., Montes, A., Tidy, A., Ashley, S., Powles, T. J.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 1994
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2033556/
https://ncbi.nlm.nih.gov/pubmed/7524607
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!